Introduction
Endometriosis is diagnosed when the functional and morphological endometrial glands and stromal structures are found outside the uterus, 1 which mainly affects women at a reproductive age. Although endometriosis is a benign disease, clinical symptoms are present, including local propagation, invasiveness and an extreme ability to proliferate under the influence of female hormones. Endometriosis most commonly occurs in the pelvis, but it also can affect the lungs, bowel, brain and abdominal wall. Abdominal wall endometriosis (AWE) usually develops due to a surgical procedure, with incidence of 0.1%. 2 According to previous literature, many patients with AWE accept surgical resection or hormonal therapy. Conventionally, wide surgical excision has been performed, compromising the musculoaponeurotic strut; thus, an incisional hernia may occur in the lower abdominal wall, in the absence of the posterior sheath of the rectus abdominis. [3] [4] [5] In addition, the success rate of medication has been reported to be low, offering only temporary alleviation of clinical symptoms. 6 Recently, more and more women with benign tumours in China have received ultrasound-guided high-intensity focused ultrasound (USgHIFU) treatment, which is a non-invasive and effective treatment. This study sought to explore the feasibility of USgHIFU as a therapy for AWE.
Materials and methods

Patients
From August 2010 to April 2014, 32 patients with AWE who were evaluated by both gynaecologists and USgHIFU physicians, have been treated with USgHIFU in our hospital. Every patient signed an informed consent form at enrollment.
The inclusion criteria of AWE were as follows: (1) women of reproductive age who had AWE mass after uterine surgery; (2) presence of local pain in the abdominal wall scar tissue during menses and absence of it after menses; (3) determination of the location and depth of the nodule in the abdominal wall incision scar by ultrasound and magnetic resonance imaging (MRI). Exclusion criteria included: pregnant women; suspected or confirmed malignancy.
USgHIFU treatment
The protocol of USgHIFU treatment for AWE is similar to that for uterine fibroids and adenomyosis. All patients were required to undergo specific bowel preparation 3 days before USgHIFU treatment, which included ingesting liquid food for 3 days, fasting for 12 hours pretreatment and a mandatory enema was administered in the morning of the treatment day. The hair on the abdominal wall was shaved from the umbilicus to the upper margin of the pubic symphysis, and the area was disinfected with 75% ethanol solution to remove oils from the skin before treatment.
USgHIFU treatment was performed under conscious sedation with JC 200 Tumour Therapeutic System (Chongqing Haifu Medical Technology Co, Ltd, Chongqing, China). An ultrasound device (MyLab 70; Esaote, Genova, Italy) was used to provide real-time imaging for monitoring and targeting the endometriosis lesions. Every patient was carefully positioned on the USgHIFU treatment bed with the anterior abdominal wall in contact with the degassed water balloon, which was a good acoustic pathway and reduced abdominal skin temperature. The power for point sonication was 50-150 W and the treatment was terminated when the hyperechoic area covered the entire treated lesion. Contrast-enhanced ultrasound was performed before and after USgHIFU to evaluate the response of the lesions to USgHIFU treatment. The patient's blood pressure, pulse, respiration rate and peripheral oxygenation were monitored continuously, and the patients were asked to report any discomfort.
Post-USgHIFU treatment follow up
After USgHIFU ablation, all patients were closely observed for complications such as skin burn and abdominal pain. During the follow-up period, changes in nodules on ultrasound or MRI were reported. The disappearance of cyclic pain and blood flow of nodules on the ultrasound or/and on the MRI in the target region were considered to be indications of successful treatment.
Statistical analysis
Statistical analysis was performed using SPSS 10.0 software (SPSS Inc., Chicago, IL, USA). All results are reported as median or mean AE standard deviation. Statistical analysis was performed by analysis of variance followed by one-way analysis of variance and the Student-Newman-Keuls test, which was used as a post hoc test. A P-value of <0.05 was considered to indicate a statistically significant difference.
Results
Patients and lesions
All patients were given ultrasound and MRI examinations before USgHIFU treatment. The nodules were found to appear hypoechoic or heterogeneous with scattered internal echoes on ultrasound, most of which appeared completely solid; only two nodules had some cystic changes internal of AWE. Scar endometriosis is usually thought to result from iatrogenic implantation of the endometrium or endometrial tissue during abdominal surgery. In this study, 26 patients had only one nodule at the corner site of the surgical scar, five patients had two nodules, and one patient had three small nodules surrounding the scar. Among the 39 lesions, 24 nodules were located in subcutaneous layer of the skin, 14 in abdominal muscle, and 1 in peritoneum. Thirty-one patients had histories of caesarean sections, and one patient a history of hysterectomy. The time interval between uterine surgery and the onset of a painful abdominal wall nodule ranged from 6 to 36 months (median of 11 months). The size of the nodule ranged from 1.0 to 5.0 cm (median of 2.4 cm). According to the four-category scale of Mehlisch for reporting dysmenorrhea pain (no pain, mild pain, moderate pain and severe pain), 7 mild pain appeared in 16 patients, moderate pain in 15 patients, and severe pain in one patient (Table 1) .
USgHIFU treatment evaluation
Detailed USgHIFU treatment results are shown in Table 2 . The total room time, including preparation time when the patient entered treatment room until they left the room to rest and observation time, ranged from 1.3 to 2.3 hours (median of 1.46 hours); the total treatment time, defined from the first energy exposure to last energy exposure, was 0.68 AE 0.36 hours; the sonication power ranged from 50 to 150 W (median of 100 w). The non-perfused volume (indicative of successful ablation), which was observed in all patients immediately after treatment, ranged from 0.9 to 2.1 cm 3 (median of 1.6 cm 3 ); the fractional ablation (defined as the non-perfused volume divided by the nodule volume) ranged from 87% to 100% (mean of 94%) ( Table 2 ).
Post-procedure evaluation
All patients were required to report any discomfort or adverse effects in 3 days post-USgHIFU and to return to our department at month 3, 6, and 12 after USgHIFU treatment. During the follow-up period, cyclic pain disappeared in 29 patients, pain remarkably decreased in three patients, and nodules gradually shrank in the treated area. In the 32 patients, with 39 nodules, the average size of AWE volume at month 6 month after USgHIFU treatment was smaller than that before treatment. The cyclic pain rating score, the main symptom indicator in all patients, at 6 months after treatment was significantly lower than that before treatment (Table 3) .
Adverse effects during and after USgHIFU treatment
During the procedure of USgHIFU, every patient reported mild pain in the treated region during sonication; however, the pain score was <3 points, and no one complained of unbearable pain.
After treatment, 32 patients reported mild pain or discomfort in the treated region. Local edema in the treated skin area was observed in 26 patients, which subsided with a 30-minute ice compress. All patients returned to their daily routines 2 hours after USgHIFU treatment and the swelling gradually disappeared within 3 days. No one complained of any severe discomfort related to USgHIFU treatment, such as blisters or skin burns (Table 4) .
Discussion
Over the last 10 years, USgHIFU has been widely used to treat uterine fibroids and adenomyosis in China. [8] [9] [10] The underlying mechanism for USgHIFU treatment involves thermal tissue destruction by focusing the ultrasound beams on a given target. The ultrasound beams go through the skin without damaging overlying and adjacent structures, even within the path of the beam up to the precise focal point, where the temperature sharply rises up to >70°C, which leads to coagulation necrosis. 11 To the best of our knowledge, only a few papers reported USgHIFU treatment for AWE in a small number of cases.
12,13 Our Pain rating scale: A scale from 0 to 10 is used to measure how severe the pain is: 0, painless; 1-3, mild pain; 4-6, moderate pain; 7-10, severe pain. Significant differences were observed between pretreatment and 6 months post-treatment. A scale from 0 to 10 is used to measure how severe the pain is: 0, painless; 1-3, mild pain; 4-6, moderate pain; 7-10, severe pain. Significant differences were observed between pretreatment and 6 months post-treatment. *A significant difference was observed between the two groups, P < 0.05. results indicate that USgHIFU can safely achieve virtually complete necrosis of AWE (Table 3) . During the 1-to 2-year follow up, it was found that the size of patients' lesions was significantly reduced, and the difference in each pain score was also statistically significant. Patients had not experienced recurrence by the end of the follow-up period, nor did anyone need surgery or oral medication again. Previous studies have shown that the changes in grey-scale during treatment correlate well with the necrosis volume of target tissues. 14 To ensure the elimination of potential endometrial tissue, the hyperechoic area should include not only the nodules but also a 1-cm area surrounding the nodules, consistent with the operation principles of AWE.
How can one determine whether AWE ablation is complete? According to previous literature, magnetic resonance imaging (MRI) had been a sensitive tool to detect thermal lesions during treatment; however, it is employed anymore due to its low cost-effectiveness, and has gradually been replaced by ultrasound. In China, USgHIFU treatment is becoming a common mode of treatment for AWE, as results have shown that ultrasound grey-scale values are reliable for defining coagulation necrosis and controlling therapeutic dose. To be consistent with previous studies, the ultrasound grey-scale was applied to evaluate ablation lesions of the nodules during treatment (Tables 1 and 2 ). Besides the grey-scale change, a microbubble-enhancing contrast ('SonoVue') was also employed to assess the surrounding blood flow of AWE when the value grey-scale appeared. If there was blood flow signal in the lesion, repeated treatment was performed until the flow signal disappeared and the desired non-perfusion area appeared. The non-perfused volume of nodules was 1.63 AE 0.48 cm 3 after treatment, and the fractional ablation reached 94% as compared with that before treatment.
Our study validates the feasibility and effectiveness of the technique and it also suggests that USgHIFU is safely repeatable in patients with AWE, which is especially important for patients with scars surrounding target tissues in the future studies. After USgHIFU treatment, the blood flow signal of AWE, as shown on colour Doppler ultrasound, disappeared immediately (Tables 1 and 2) , and the lesion of AWE gradually decreased, most of the lesion disappearing during 1-year follow up. No contrast enhancement was detected in the lesions treated with MRI after USgHIFU treatment.
With accurate real-time imaging guidance, well-demarcated coagulation tissue could be obtained without damaging the surrounding tissues. This technique has proven safe and effective for the treatment of both superficial and deep benign/malignant tumours. In the case of the nodule of AWE, safety was also a main concern. To reduce possible risk, the transducer and high-frequency diagnostic ultrasound probe were used to provide real-time imaging of AWE and their surrounding tissues. To avoid skin damage, the treatment exposure was intermittently applied and the ratio of sonication/rest was 1:2. Besides, the degassed water balloons could reduce the temperature of the skin, which would not absorb too great a therapeutic dose. In this study, no severe complications occurred during the treatment or follow-up period. Our results show that treatment with USgHIFU has fewer complications and adverse effects than conventional treatments. Surgical treatment was too often recommended when conventional wide excision compromised the musculoaponeurotic strut, and a potential incisional hernia in the lower abdominal wall was formed, in the absence of the posterior sheath of the rectus abdominis. 1 The large defect after treatment of tissues definitely made the primary closure difficult and could cause various wound complications such as dehiscence, haematoma, seroma, hypertrophic scar and asymmetry of the abdominal wall or dog-ear deformities. 15 To decrease the impact of lifestyle on surgery, hormonal therapy had been used for the treatment of AWE, but the use of progestogens, oral contraceptive pills and danazol are not effective because medical treatment gives only partial relief. 16 In addition, the high risk recurrence rate after cessation therapy reported in the previous literature was 4.3-9.1% and the operations were performed again in 10-year follow-up period. 17, 18 The limitations of this study are as follows. First, it is a retrospective study with a small number of subjects. This study is also limited by the relatively short follow-up period. Future studies with a large number of subjects and longer follow-up period are needed to determine the longterm recurrence rate and the re-intervention rate.
Conclusions
Based on our results from a relatively small number of subjects, USgHIFU can be used safely in treating AWE. Although studies with a large number of subjects and a longer follow-up time are needed, there is evidence that USgHIFU may be an alternative to traditional surgery or hormonal therapy in future.
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